Joel Greenblatt's LLY Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 8,016 shares of Eli Lilly and Company (LLY) worth $6.12 M, representing 0.03% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in LLY, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2017, adding 410,286 shares. Largest reduction occurred in Q2 2017, reducing 439,592 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Eli Lilly and Company (LLY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Eli Lilly and Company (LLY) Trades by Joel Greenblatt
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +39,412 | Add 0.00% | 39,411 | $49.12 |
| Q3 2013 | +7,350 | Add 18.65% | 46,761 | $50.32 |
| Q4 2013 | +94,360 | Add 201.79% | 141,121 | $51.00 |
| Q1 2014 | -132,105 | Reduce 93.61% | 9,016 | $58.90 |
| Q2 2014 | -1,267 | Reduce 14.05% | 7,749 | $62.20 |
| Q3 2014 | -2,121 | Reduce 27.37% | 5,628 | $64.85 |
| Q4 2014 | +6 | Add 0.11% | 5,634 | $69.05 |
| Q1 2015 | -5,634 | Sold Out | 5,634 | $0.00 |
| Q4 2016 | +38,305 | New Buy | 38,305 | $73.54 |
| Q1 2017 | +410,286 | Add 1071.10% | 448,591 | $84.11 |
| Q2 2017 | -439,592 | Reduce 97.99% | 8,999 | $82.34 |
| Q3 2017 | -8,999 | Sold Out | 8,999 | $0.00 |
| Q4 2017 | +256,537 | New Buy | 256,537 | $84.46 |
| Q1 2018 | -165,912 | Reduce 64.67% | 90,625 | $77.37 |
| Q2 2018 | -90,625 | Sold Out | 90,625 | $0.00 |
| Q3 2018 | +69,828 | New Buy | 69,828 | $107.31 |
| Q4 2018 | +242,632 | Add 347.47% | 312,460 | $115.72 |
| Q1 2019 | -66,667 | Reduce 21.34% | 245,793 | $129.76 |
| Q2 2019 | +257,782 | Add 104.88% | 503,575 | $110.79 |
| Q3 2019 | -397,920 | Reduce 79.02% | 105,655 | $111.83 |
| Q4 2019 | -105,655 | Sold Out | 105,655 | $0.00 |
| Q1 2021 | +3,552 | New Buy | 3,552 | $186.94 |
| Q2 2021 | -1,667 | Reduce 46.93% | 1,885 | $229.71 |
| Q3 2021 | +31,854 | Add 1689.87% | 33,739 | $231.04 |
| Q4 2021 | -31,213 | Reduce 92.51% | 2,526 | $276.33 |
| Q1 2022 | +814 | Add 32.22% | 3,340 | $286.23 |
| Q2 2022 | +81 | Add 2.43% | 3,421 | $324.17 |
| Q3 2022 | +198 | Add 5.79% | 3,619 | $323.29 |
| Q4 2022 | +58 | Add 1.60% | 3,677 | $365.84 |
| Q1 2023 | +42 | Add 1.14% | 3,719 | $343.42 |
| Q2 2023 | -224 | Reduce 6.02% | 3,495 | $468.98 |
| Q3 2023 | +3,891 | Add 111.33% | 7,386 | $537.13 |
| Q4 2023 | +1,878 | Add 25.43% | 9,264 | $582.92 |
| Q1 2024 | +620 | Add 6.69% | 9,884 | $777.96 |
| Q2 2024 | +2,065 | Add 20.89% | 11,949 | $905.38 |
| Q3 2024 | -3,434 | Reduce 28.74% | 8,515 | $885.94 |
| Q4 2024 | -2,736 | Reduce 32.13% | 5,779 | $772.00 |
| Q1 2025 | +1,768 | Add 30.59% | 7,547 | $825.91 |
| Q2 2025 | -361 | Reduce 4.78% | 7,186 | $779.53 |
| Q3 2025 | +830 | Add 11.55% | 8,016 | $763.00 |
Joel Greenblatt's Eli Lilly and Company Investment FAQs
Joel Greenblatt first purchased Eli Lilly and Company (LLY) in Q2 2013, acquiring 39,411 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Eli Lilly and Company (LLY) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's largest addition to Eli Lilly and Company (LLY) was in Q1 2017, adding 448,591 shares worth $37.73 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 8,016 shares of Eli Lilly and Company (LLY), valued at approximately $6.12 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Eli Lilly and Company (LLY) represents approximately 0.03% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's peak holding in Eli Lilly and Company (LLY) was 503,575 shares, as reported at the end of Q2 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.